1-Cyclopropyl-6-Fluoro-7-[(1S,4S)-5-Methyl-2,5-Diazabicyclo[2.2.1]Hept-2-Yl]-4-Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid Monomethanesulfonate; Danofloxacin Methanesulfonate; 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-7-[(1S,4S)-5-Methyl-2,5-Diazabicyclo[2.2.1]Hept-2-Yl]-4-Oxo-3-Quinolinecarboxylic Acid Mesylate; Dafloxacin Mesylate

Brief Introduction

This product is a fluoroquinolone synthetic antibacterial agent, mainly through the inhibition of bacterial DNA gyrase.

Alpha-Methylcinnamic Acid

CAS:1199-77-5

Molecular Formula:C10H10O2

Alias

More Information

α-Methylcinnamic Acid; 2-Methyl-3-Phenylacrylic Acid; 2-Methyl-3-Phenyl-2-Propenoic Acid; (E)-2-Methyl-3-Phenylacrylic Acid; (2E)-2-Methyl-3-Phenylacrylic Acid

Brief Introduction

This product can be used as flavors and fragrances, and can also be used as pharmaceutical intermediates.

4-Bromocinnamic Acid

CAS:1200-07-3

Molecular Formula:C9H7BrO2

Alias

More Information

3-(4-Bromophenyl)Acrylic Acid; Trans-4-Bromocinnamic Acid; 4-Bromo-Trans-Cinnamic Acid; Bromocinnamic Acid,4-; P-Bromocinnamic Acid

Brief Introduction

P-bromocinnamic acid is an intermediate in organic synthesis.

Trans-2,4-Dichlorocinnamic Acid

CAS:1201-99-6

Molecular Formula:C9H6Cl2O2

Alias

More Information

2-Propenoic Acid, 3-(2,4-Dichlorophenyl)-; 2,4-Dichlorocinnamic Acid; 3-(2,4-Dichlorophenyl)-2-Propenoicacid; 3-(2,4-Dichlorophenyl)Propenoic Acid

Brief Introduction

This product can be used as pharmaceutical intermediate

(3S,3'R,4'S,5'S,6'R)-5-[(4-Ethylphenyl)Methyl]-6'-(Hydroxymethyl)Spiro[1H-2-Benzofuran-3,2'-Oxane]-3',4',5'-Triol,Hydrate

CAS:1201913-82-7

Molecular Formula:C22H28O7

Alias

More Information

Tofogliflozin Hydrate; Tofogliflozin (Hydrate); Tofogliflozin Monohydrate; Unii-P8Dd8Kx4O4; (1S,3'R,4'S,5'S,6'R)-6-(4-Ethylbenzyl)-6'-(Hydroxymethyl)-3',4',5',6'-Tetrahydro-3H-Spiro[Isobenzofuran-1,2'-Pyran]-3',4',5'-Triol Hydrate; Tofogliflozin

Brief Introduction

Tofogliflozin is a SGLT-2 inhibitor type 2 diabetes drug developed by Chinese and foreign pharmaceutical companies. It is a sodium glucose co transporter 2 inhibitor. Its advantage lies in its high selectivity. The drug plays a hypoglycemic effect by inhibiting the reabsorption of glucose by the kidneys and inducing excessive glucose excretion in the blood. The compound has a unique mechanism independent of insulin. In addition to improving fasting blood glucose and postprandial blood glucose, it also has low-risk hypoglycemia inducing events and has a significant effect on weight loss.

1
···
83
84
85
86
87
88
89
···
265

Inquiry (

/ 10

)

Clear All